Equities research analysts forecast that Inogen Inc (NASDAQ:INGN) will post earnings of $0.21 per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Inogen’s earnings, with estimates ranging from $0.17 to $0.26. Inogen reported earnings per share of $0.25 in the same quarter last year, which indicates a negative year-over-year growth rate of 16%. The company is scheduled to issue its next earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Inogen will report full year earnings of $1.19 per share for the current year, with EPS estimates ranging from $1.17 to $1.21. For the next financial year, analysts expect that the firm will report earnings of $1.48 per share, with EPS estimates ranging from $1.42 to $1.54. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Inogen.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. During the same period last year, the company earned $0.25 EPS.
In other news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $119.92, for a total value of $1,678,880.00. Following the transaction, the director now directly owns 7,808 shares in the company, valued at approximately $936,335.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Heath Lukatch sold 2,500 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $126.40, for a total value of $316,000.00. The disclosure for this sale can be found here. Insiders sold a total of 113,651 shares of company stock worth $13,299,463 over the last quarter. Corporate insiders own 5.31% of the company’s stock.
Several large investors have recently bought and sold shares of INGN. Koch Industries Inc. boosted its position in shares of Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Inogen by 77.4% in the 2nd quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock worth $37,138,000 after purchasing an additional 169,778 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Inogen by 91.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 128,043 shares of the medical technology company’s stock worth $12,217,000 after purchasing an additional 61,291 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Inogen by 78.2% in the 3rd quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock worth $11,801,000 after purchasing an additional 54,467 shares during the last quarter.
Shares of Inogen (NASDAQ INGN) traded up $3.13 on Friday, reaching $118.12. The company’s stock had a trading volume of 118,040 shares, compared to its average volume of 123,945. The company has a market cap of $2,399.88, a price-to-earnings ratio of 96.03, a price-to-earnings-growth ratio of 3.90 and a beta of 1.13. Inogen has a 52-week low of $62.69 and a 52-week high of $130.05.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.